Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.
An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.
An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that isolated thrombocytopenia with mucosal bleeding and petechiae is highly suggestive of ITP, while underscoring the importance of ruling out other causes—especially drug-induced thrombocytopenia—through careful evaluation.
Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.
Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease.
Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.
Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.
Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.
Panelists discuss how the evaluation process must evolve to accommodate therapies that show benefits in slowing atrophy and motor decline over 1 to 2 years, emphasizing the need for early coverage rather than waiting for extensive long-term data.
Panelists discuss the mechanisms of action of gene therapy for NF1-associated plexiform neurofibromas, focusing on restoring functional neurofibromin to regulate the RAS/MAPK pathway and prevent tumor formation, while highlighting promising early clinical trial results showing reduced tumor volume and improved symptoms, alongside the need for further studies to assess long-term safety and efficacy.
Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.
Panelists discuss how disability progression can be measured through practical clinical tools like patient-reported outcomes, timed walking tests, and dexterity assessments rather than relying solely on relapse rates.
An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to the FDA, considering patient-reported outcomes beyond just high-grade toxicities, and working closely with specialists like ophthalmologists using standardized assessment tools and treatment algorithms to manage drug-specific adverse effects like visual complications from folate receptor–targeting therapies.
Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.
Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and collaboration drive the growing integration of SubQ formulations as a convenient and adaptable option in cancer care.
Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the broader adoption of subcutaneous (SubQ) oncology therapies, underscoring the need for coordinated stakeholder collaboration and education to drive integration.
Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit patients, potentially allowing for treatment-free intervals after achieving deep responses.
A panelist emphasizes that while trispecific antibodies offer near-perfect response rates and convenient monthly dosing that could improve quality of life, careful assessment of adverse effects like infections and taste disturbances is crucial—especially for lower-risk patients—making patient preference and physician judgment key in determining their optimal use, with high-risk patients with heavily pretreated disease poised to benefit most.
Panelists discuss how to balance achieving deeper MRD-negative responses against increased toxicity risks in transplant-ineligible patients by personalizing therapy through dose modifications, weekly vs twice-weekly dosing schedules, and careful monitoring while maintaining treatment intensity similar to clinical trials.
Panelists discuss how concurrent comorbidities, such as thyroid disorders and other autoimmune conditions, are commonly seen in patients with alopecia areata (AA) and how they complicate disease management and increase the overall burden on patients.
A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting that menin inhibitors (including the already-approved revumenib and pipeline agents like ziftomenib, bleximenib, and enzomenib) are the most exciting emerging therapies targeting 40% to 50% of patients with acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements, though significant therapeutic gaps remain for challenging subgroups like TP53-mutated disease.
A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause mortality between intensive chemotherapy and azacitidine plus venetoclax, but with lower adverse events in the azacitidine-venetoclax group, suggesting that treatment selection should be individualized based on patient fitness, genetic mutations, transplant candidacy, and patient preferences for time-limited vs continuous therapy, while emphasizing the need for prospective randomized trials to definitively guide treatment decisions in this age group.
Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for provider education, clinical decision support, and multidisciplinary collaboration to promote earlier recognition and more effective, coordinated care.
Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered approaches to address the physical, emotional, and social burden of the disease.
Panelists expressed cautious optimism about high-risk acute myeloid leukemia (AML) treatment, emphasizing the need for ongoing research, personalized therapy based on molecular profiling, and strengthened collaboration between community and academic centers to improve patient outcomes, while recognizing that education and sharing best practices are key to advancing targeted therapies and achieving long-term cures.
Panelists highlight that patient advocacy is crucial in improving high-risk acute myeloid leukemia (AML) outcomes by providing emotional support, funding research, influencing clinical guidelines, promoting patient engagement, facilitating collaboration between community and academic care, addressing systemic access barriers, and implementing innovative programs like medication recycling to enhance treatment availability.
Panelists discuss how reaching underserved populations requires proactive outreach, digital health tools with appropriate training, addressing health literacy barriers, and ensuring equitable access to diabetes technologies and treatments rather than waiting for patients to seek care.
Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather than applying traditional step therapy protocols that may delay optimal treatment.
Panelists discuss how clinical decision support tools, care pathways, and artificial intelligence can address primary care workforce shortages by providing real-time guidance, predictive modeling for high-risk patients, and autonomous agents for patient outreach and care coordination.
Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and neurodegenerative aspects of MS, particularly for progressive forms where treatment options are limited.
